Amplia Therapeutics Ltd has released a press release.
ACCENT Trial Recruitment Progress
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Quarterly Activities and Cashflow Reports - March 23 Qtr
- First Patient Recruited to Cohort 3 of ACCENT Trial
- Dose Escalation Approved in ACCENT Clinical Trial of AMP945
- First Patient Recruited to Cohort 2 of Accent Trial
- Quarterly Activities and Cashflow Reports - December 2022
Later from Amplia Therapeutics
- Amplia receives grant to collaborate with CSIRO
- Grant to collaborate with CSIRO Supplementary Announcement
- AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
- Annual Report to Shareholders
- ATX Quarterly Activities and Cashflow Reports - June 23 Qtr
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics